Intellia Therapeutics Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.0%projected annual EPS growth
Analyst Coverage
17analysts covering
FY EPS (est.)
-$3.15next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
HAELO placebo-adjusted reduction in mean monthly HAE attacks Quarterly87.0Target: Maintain at least 80% efficacy through longer follow-up
HAELO patients both attack-free and ongoing-therapy-free Quarterly62.0Target: Maintain at least 50% through longer follow-up
MAGNITUDE-2 Phase 3 enrollment MonthlyTarget: Complete enrollment by 2026-12-31
Watch Items
- Lonvo-z BLA acceptance timingAction: Reassess the regulatory probability, launch timing, and scenario price targets if FDA acceptance is not announced within the company-guided second half of 2026.
- Nex-z hepatic safety after Phase 3 enrollment resumedAction: Reassess nex-z risk adjustment and the viability of both MAGNITUDE programs immediately after any qualifying event.
Research as of 29 Aug 2026